At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 22 enrolled
Drug / intervention
abaloparatide-sMTScombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Single Arm Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Usability of Abaloparatide-sMTS in Postmenopausal Women With Low Bone Mineral Density
In Brief
A Phase 1 clinical trial evaluating abaloparatide-sMTS for Postmenopausal Osteoporosis. Completed, enrolled 22 participants across 1 site.
Detailed Summary
This was an open-label, single-center study to evaluate the usability of abaloparatide-sMTS by participants with low BMD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostmenopausal Osteoporosis
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
Enrollment StartApr 2019
Primary CompletionMay 2019
First PostedApr 2020
TodayJul 2026
First PostedApr 29, 2020
Enrollment StartApr 9, 2019
Primary CompletionMay 14, 2019
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 6.2 years ago
Interventions
abaloparatide-sMTScombination
Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide coated onto an sMTS array for transdermal administration of abaloparatide.